289 related articles for article (PubMed ID: 28624905)
1. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
2. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
4. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
6. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
[TBL] [Abstract][Full Text] [Related]
7. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
8. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.
Ayala M; Ávila E; Domínguez J; Aquino X; Vela J
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):57-62. PubMed ID: 26699851
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Gratwohl A; Pfirrmann M; Zander A; Kröger N; Beelen D; Novotny J; Nerl C; Scheid C; Spiekermann K; Mayer J; Sayer HG; Falge C; Bunjes D; Döhner H; Ganser A; Schmidt-Wolf I; Schwerdtfeger R; Baurmann H; Kuse R; Schmitz N; Wehmeier A; Fischer JT; Ho AD; Wilhelm M; Goebeler ME; Lindemann HW; Bormann M; Hertenstein B; Schlimok G; Baerlocher GM; Aul C; Pfreundschuh M; Fabian M; Staib P; Edinger M; Schatz M; Fauser A; Arnold R; Kindler T; Wulf G; Rosselet A; Hellmann A; Schäfer E; Prümmer O; Schenk M; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Büsche G; Haferlach C; Schnittger S; Müller MC; Reiter A; Berger U; Saußele S; Hochhaus A; Hehlmann R; ;
Leukemia; 2016 Mar; 30(3):562-9. PubMed ID: 26464170
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Lee SJ; Kukreja M; Wang T; Giralt SA; Szer J; Arora M; Woolfrey AE; Cervantes F; Champlin RE; Gale RP; Halter J; Keating A; Marks DI; McCarthy PL; Olavarria E; Stadtmauer EA; Abecasis M; Gupta V; Khoury HJ; George B; Hale GA; Liesveld JL; Rizzieri DA; Antin JH; Bolwell BJ; Carabasi MH; Copelan E; Ilhan O; Litzow MR; Schouten HC; Zander AR; Horowitz MM; Maziarz RT
Blood; 2008 Oct; 112(8):3500-7. PubMed ID: 18664621
[TBL] [Abstract][Full Text] [Related]
13. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
16. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.
Nicolini FE; Alcazer V; Cony-Makhoul P; Heiblig M; Morisset S; Fossard G; Bidet A; Schmitt A; Sobh M; Hayette S; Mahon FX; Dulucq S; Etienne G
Exp Hematol; 2018 Aug; 64():97-105.e4. PubMed ID: 29800673
[TBL] [Abstract][Full Text] [Related]
18. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.
Jiang Q; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang H; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Lai YY; Huang XJ
Blood; 2011 Mar; 117(11):3032-40. PubMed ID: 21252092
[TBL] [Abstract][Full Text] [Related]
20. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
